445 related articles for article (PubMed ID: 36311748)
21. Osteosarcoma in Children: Not Only Chemotherapy.
Argenziano M; Tortora C; Pota E; Di Paola A; Di Martino M; Di Leva C; Di Pinto D; Rossi F
Pharmaceuticals (Basel); 2021 Sep; 14(9):. PubMed ID: 34577623
[TBL] [Abstract][Full Text] [Related]
22. Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma.
Zhou Y; Liu B; Wang M; Ni J
Pediatr Blood Cancer; 2014 Apr; 61(4):612-7. PubMed ID: 24123836
[TBL] [Abstract][Full Text] [Related]
23. Deciphering chemoresistance in osteosarcoma: Unveiling regulatory mechanisms and function through the lens of noncoding RNA.
Chen H; Gong Z; Zhou H; Han Y
Drug Dev Res; 2024 Apr; 85(2):e22167. PubMed ID: 38444106
[TBL] [Abstract][Full Text] [Related]
24. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
Wang YT; Tang F; Hu X; Zheng CX; Gong TJ; Zhou Y; Luo Y; Min L
IUBMB Life; 2020 Oct; 72(10):2146-2153. PubMed ID: 33448097
[TBL] [Abstract][Full Text] [Related]
25. Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.
Nomura M; Rainusso N; Lee YC; Dawson B; Coarfa C; Han R; Larson JL; Shuck R; Kurenbekova L; Yustein JT
J Natl Cancer Inst; 2019 Nov; 111(11):1216-1227. PubMed ID: 30793158
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA‑487b‑3p inhibits osteosarcoma chemoresistance and metastasis by targeting ALDH1A3.
Cheng M; Duan PG; Gao ZZ; Dai M
Oncol Rep; 2020 Dec; 44(6):2691-2700. PubMed ID: 33125503
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
[TBL] [Abstract][Full Text] [Related]
28. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.
Wang W; Zhao HF; Yao TF; Gong H
Invest New Drugs; 2019 Feb; 37(1):175-183. PubMed ID: 30353245
[TBL] [Abstract][Full Text] [Related]
29. Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal.
Li S; Sun W; Wang H; Zuo D; Hua Y; Cai Z
Tumour Biol; 2015 Mar; 36(3):1329-38. PubMed ID: 25666750
[TBL] [Abstract][Full Text] [Related]
30. Notch1 is associated with the multidrug resistance of hypoxic osteosarcoma by regulating MRP1 gene expression.
Li C; Guo D; Tang B; Zhang Y; Zhang K; Nie L
Neoplasma; 2016; 63(5):734-42. PubMed ID: 27468877
[TBL] [Abstract][Full Text] [Related]
31. Macrophage migration inhibitory factor promotes osteosarcoma growth and lung metastasis through activating the RAS/MAPK pathway.
Wang C; Zhou X; Li W; Li M; Tu T; Ba X; Wu Y; Huang Z; Fan G; Zhou G; Wu S; Zhao J; Zhang J; Chen J
Cancer Lett; 2017 Sep; 403():271-279. PubMed ID: 28642171
[TBL] [Abstract][Full Text] [Related]
32. MiR-34c inhibits osteosarcoma metastasis and chemoresistance.
Xu M; Jin H; Xu CX; Bi WZ; Wang Y
Med Oncol; 2014 Jun; 31(6):972. PubMed ID: 24802328
[TBL] [Abstract][Full Text] [Related]
33. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT
Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780
[TBL] [Abstract][Full Text] [Related]
34. Comparative Immunology and Immunotherapy of Canine Osteosarcoma.
Mason NJ
Adv Exp Med Biol; 2020; 1258():199-221. PubMed ID: 32767244
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.
Liapis V; Labrinidis A; Zinonos I; Hay S; Ponomarev V; Panagopoulos V; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
Cancer Lett; 2015 Feb; 357(1):160-169. PubMed ID: 25444931
[TBL] [Abstract][Full Text] [Related]
36. Leptin acts on mesenchymal stem cells to promote chemoresistance in osteosarcoma cells.
Feng H; Zhang Q; Zhao Y; Zhao L; Shan B
Aging (Albany NY); 2020 Apr; 12(7):6340-6351. PubMed ID: 32289750
[TBL] [Abstract][Full Text] [Related]
37. Advancing Tissue Factor-targeted Therapy for Osteosarcoma
Ichikawa J; Schoenecker JG; Tatsuno R; Kawasaki T; Suzuki-Inoue K; Haro H
Curr Pharm Des; 2023; 29(13):1009-1012. PubMed ID: 37069710
[TBL] [Abstract][Full Text] [Related]
38. CAR T targets and microenvironmental barriers of osteosarcoma.
Zhu J; Simayi N; Wan R; Huang W
Cytotherapy; 2022 Jun; 24(6):567-576. PubMed ID: 35193828
[TBL] [Abstract][Full Text] [Related]
39. The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.
Pu Y; Zhao F; Li Y; Cui M; Wang H; Meng X; Cai S
BMC Cancer; 2017 Jan; 17(1):45. PubMed ID: 28073349
[TBL] [Abstract][Full Text] [Related]
40. Noncoding RNAs in osteosarcoma: Implications for drug resistance.
Lin Z; Xie X; Lu S; Liu T
Cancer Lett; 2021 Apr; 504():91-103. PubMed ID: 33587978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
